The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.75
Bid: 48.50
Ask: 49.00
Change: -0.50 (-1.02%)
Spread: 0.50 (1.031%)
Open: 48.00
High: 50.25
Low: 48.00
Prev. Close: 48.80
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Wed, 22nd Dec 2021 12:21

(Alliance News) - Stock prices were slightly higher at midday on Wednesday as investors mulled the likelihood of further Omicron restrictions being imposed and awaited US economic growth data in the afternoon.

The FTSE 100 index was up just 0.56 of a point at 7,297.79. The mid-cap FTSE 250 index was faring better, up 141.93 points, or 0.6%, at 22,962.27. The AIM All-Share index was up 4.78 points, or 0.4%, at 1,178.35.

The Cboe UK 100 index was up 0.2% at 724.37. The Cboe 250 was up 0.7% at 20,362.10. The Cboe Small Companies was up 0.4% at 14,864.54.

In mainland Europe, the CAC 40 stock index in Paris was up 0.2%, while the DAX 40 in Frankfurt was 0.3% higher.

"Investors are preparing to go into hibernation for Christmas and will hope by this time next week we'll know a lot more about the trajectory of Omicron and the likelihood of further restrictions to contain it, and just how long those curbs will be in place," said AJ Bell's Russ Mould. "For now the markets, bar the odd day, have just about managed to hold on to the idea that, to employ central bankers' favourite word of 2021, Omicron's impact will be transitory."

In the FTSE 100, Taylor Wimpey was up 1.3%.

The housebuilder committed to removing terms from contracts that double ground rents for leaseholders every 10 years, the UK Competition & Markets Authority confirmed.

Taylor Wimpey said the CMA investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings.

The High Wycombe, England-based firm said the cost of the undertakings falls within the original provision it made in 2017. By entering into the undertakings there is no finding that Taylor Wimpey has infringed UK consumer law, it noted.

At the other end of London large-caps, Croda International was the worst performer, down 1.7%. The speciality chemicals company has agreed to sell the majority of its Performance Technologies and Industrial Chemicals businesses to Cargill for an enterprise value of EUR915 million on a cash-free, debt-free basis.

Croda said the disposal of the businesses follows the strategic review that it announced in May. The operations being sold represent 77% of PTIC's 2020 revenue and consist of five manufacturing facilities in the UK, China and the Netherlands.

Land Securities was down 0.3%. The property developer bought a further stake in the Bluewater shopping mall outside London.

Landsec said it has completed the acquisition of an additional 25% share in Bluewater from Lendlease Retail Partnership for GBP172 million, representing a net initial yield of 8.15% and an equivalent yield of 8.25%.

In a separate deal, Landsec said it will sell 25% of this share - a 7.5% stake - to co-owner M&G for its pro rata share of the purchase price with the deal completing in April 2022.

M&G shares were up 1.3%.

In the FTSE 250, Syncona was the best performer, up 7.5%, after the healthcare investor said its portfolio company Gyroscope Therapeutics will be sold to Swiss pharmaceutical maker Novartis for up to USD1.5 billion.

Syncona has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016. In a bumper payday, Syncona will receive upfront cash proceeds of GBP334 million from the deal, representing a GBP180 million uplift to the current holding value.

Novartis shares were down 0.6% in Zurich.

Conversely, Grafton was down 1.1%. The Dublin-based building materials firm acquired Cork-based building materials supplier Sitetech Building Products. Grafton did not disclose a purchase price. Sitetech had revenue of EUR17 million in 2020. Grafton noted the acquisition is subject to approval by the Competition & Consumer Protection Commission in Ireland.

On AIM, Avacta was up 22% after it said its AffiDX Covid-19 antigen lateral flow test has received a CE mark for consumer self-test use in the UK and EU.

The pound was quoted at USD1.3315 at midday on Wednesday, up from USD1.3248 at the London equities close Tuesday.

UK Prime Minister Boris Johnson on Tuesday gave the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25.

The announcement gave the pound some support, said analysts at OFX.

The euro was priced at USD1.1298, higher against USD1.1267 late Tuesday. Against the Japanese yen, the dollar was trading at JPY114.20, firm from JPY114.14.

Brent oil was quoted at USD74.14 a barrel on Wednesday at midday, up from USD73.48 late Tuesday. Gold stood at USD1,790.23 an ounce, up from USD1,785.40.

US stock index futures were pointing to a mixed start on Wall Street as investors look for clarity over the economic impact of the Omicron variant and the future of the Biden administration's USD2 trillion stimulus plan.

The Dow Jones Industrial Average was called up 0.1%, the S&P 500 flat and the Nasdaq Composite down 0.1%.

The year-and-a-half-long rally across markets has petered out in recent weeks on fears about the new Covid variant and government measures to contain the spread. This comes just as central banks begin to remove the vast financial support put in place at the start of the pandemic.

US investors remain hopeful of a resolution to the latest political impasse after US President Joe Biden said he was optimistic he could win the key vote of Democratic Senator Joe Manchin, who threw the president's economic agenda into doubt after he said Sunday he would reject the present stimulus proposal.

On the corporate front, Merck & Co was up 1.8% in pre-market trade in New York. The drugmaker said the UK government has ordered an additional 1.8 million courses of molnupiravir, its investigational oral antiviral Covid-19 drug.

Wednesday's economic calendar has a third estimate on US third-quarter gross domestic product at 1330 GMT. This is expected to show an annualised increase of 2.1%, unchanged from the second reading.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
27 Mar 2023 13:44

Avacta to present tumour medicine data at cancer research meeting

(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
13 Mar 2023 10:08

Avacta has 'no relationship' with failed tech-focussed bank

(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.

Read more
17 Jan 2023 17:16

Avacta reports positive progress in chemotherapy trial

(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
8 Nov 2022 13:51

Avacta raises GBP64 million to finance Launch Diagnostics purchase

(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million.

Read more
18 Oct 2022 12:40

Avacta plans to raise GBP62 million; buys Launch Diagnostics

(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million.

Read more
18 Oct 2022 11:12

Avacta buying Launch Diagnostics for initial £24m

(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.

Read more
29 Sep 2022 11:56

Avacta losses narrow as it progresses clinical programmes

(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.

Read more
29 Sep 2022 11:30

Avacta narrows loss, multiplies revenue thanks to Therapeutics divison

(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division.

Read more
5 Sep 2022 11:07

AIM WINNERS & LOSERS: Avacta gets approval; Jubilee's Roan at capacity

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
5 Sep 2022 10:10

Avacta shares up as drug approved for soft tissue sarcoma treatment

(Alliance News) - Avacta Group PLC on Monday said it received approval for its AVA6000 for treatment of soft tissue sarcoma.

Read more
5 Sep 2022 07:16

Avacta's soft tissue sarcoma treatment gets FDA orphan drug designation

(Sharecast News) - Biotechnology company Avacta Group said on Monday that its soft tissue sarcoma treatment has been granted orphan drug designation by the US Food and Drug Administration.

Read more
1 Sep 2022 12:01

Avacta cancer drug candidate AVA6000 advances to fourth dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort.

Read more
21 Jul 2022 15:29

Avacta joint venture completes fresh funding round

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.